Patents Assigned to Boehringer Ingelheim Pharma GmbH
  • Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
    Publication number: 20040014679
    Abstract: The invention relates to an inhalation powder for treating migraine, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096] of formula I as the active substance base in the form of spherically nanostructured microparticles, and a process for the manufacture thereof.
    Type: Application
    Filed: February 12, 2003
    Publication date: January 22, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co., KG
    Inventors: Michael Trunk, Claudius Weiler
  • (R) 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1 (pyrrolidinocarbonyl)-ethyl]-benzimidazole, the monohydrochloride thereof, preparation thereof and the use as pharmaceutical composition
    Publication number: 20040010026
    Abstract: Crystalline forms of the compounds (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-(pyrrolidinocarbonyl)-ethyl]-benzimidazole and the monohydrochloride thereof, processes for the preparation thereof and the use thereof as pharmaceutical compositions.
    Type: Application
    Filed: June 17, 2003
    Publication date: January 15, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Guenter Linz, Peter Sieger, Gunnar Schreiner, Werner Rall, Rolf Schmid
  • Medicaments comprising betamimetics and a novel anticholinergic
    Publication number: 20040010003
    Abstract: A pharmaceutical composition comprising:
    Type: Application
    Filed: March 24, 2003
    Publication date: January 15, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher John Montague Meade, Michel Pairet, Ingo Konetzki
  • Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
    Publication number: 20040002510
    Abstract: The invention relates to a crystalline micronisate of (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
    Type: Application
    Filed: March 10, 2003
    Publication date: January 1, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Helmut Bender, Hagen Graebner, Konrad Schindler, Michael Trunk, Michael Walz
  • Medicament combinations comprising heterocyclic compounds and a novel anticholinergic
    Publication number: 20040002502
    Abstract: The present invention relates to novel pharmaceutical compositions based on a new anticholinergic 1 and heterocyclic compounds 2, processes for preparing them and their use in the treatment of respiratory complaints.
    Type: Application
    Filed: April 8, 2003
    Publication date: January 1, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher John Montague Meade, Michel Pairet
  • Method for the administration of an anticholinergic by inhalation
    Publication number: 20030235538
    Abstract: An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 {square root}{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 &mgr;m, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 &mgr;m to 500 &mgr;m, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 {square root}{square root over (kPa)} min/L containing the inhalable powder.
    Type: Application
    Filed: April 4, 2003
    Publication date: December 25, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Bernd Zierenberg
  • Process for preparing beta-L-2'deoxy-thymidine
    Publication number: 20030236397
    Abstract: The present invention relates to a new, essentially four-step process for preparing beta-L-2′-deoxy-thymidine starting from L-arabinose. The process according to the invention is particularly important for mass production of beta-L-2′-deoxy-thymidine.
    Type: Application
    Filed: April 14, 2003
    Publication date: December 25, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Franz Dietrich Klingler, Paul Kreye, Wolfgang Baumgarten
  • Industrial process for preparing tropenol
    Publication number: 20030236409
    Abstract: The invention relates to a new industrially useable process for preparing tropenol, optionally in the form of the acid addition salts thereof.
    Type: Application
    Filed: May 29, 2003
    Publication date: December 25, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Gisela Bodenbach, Andreas Mathes, Helmut Meissner, Peter Specht
  • New drug combinations for the treatment of ischaemic conditions
    Publication number: 20030235576
    Abstract: The invention relates to new drug combinations based on sodium channel blockers 1 and fibrinolytics 2, processes for the preparation thereof as well as the use thereof for preparing pharmaceutical compositions for the treatment of ischaemic conditions.
    Type: Application
    Filed: June 12, 2003
    Publication date: December 25, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Hermann Duettmann, Annerose Mauz, Sophie Banzet
  • Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
    Publication number: 20030236282
    Abstract: The present invention relates to substituted piperidines of general formula 1
    Type: Application
    Filed: March 13, 2003
    Publication date: December 25, 2003
    Applicant: Boehringer ingelheim Pharma GmbH & Co.
    Inventors: Rudolf Hurnaus, Klaus Rudolf, Stephan Georg Mueller, Dirk Stenkamp, Philipp Lustenberger, Alexander Dreyer, Kai Gerlach, Marcus Schindler, Kirsten Arndt, Eckhart Bauer
  • Agents with antidepressant action, containing pramipexol and second antidepressant
    Patent number: 6667329
    Abstract: The present invention relates to the use of 2-amino-4,5,6,7-tetrahydro-6-propylamino-benzothiazole (pramipexole), the (+)- or (−)-enantiomer thereof or one of the pharmacologically acceptable salts thereof in conjunction with another antidepressant for the improved treatment of depression and depressive states.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: December 23, 2003
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Jerzy Maj
  • New difurylglycolic acid esters, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
    Publication number: 20030229227
    Abstract: Difurylglycolic acid esters of the formula 1 1
    Type: Application
    Filed: March 4, 2003
    Publication date: December 11, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerd Morschhaeuser, Michael P. Pieper, Georg Speck
  • Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
    Publication number: 20030225089
    Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.
    Type: Application
    Filed: April 7, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Birgit Jung, Michel Pairet, Michael P. Pieper, Hans Clemens Reiser
  • Medicaments comprising steroids and a novel anticholinergic
    Publication number: 20030223937
    Abstract: A pharmaceutical composition comprising:
    Type: Application
    Filed: March 19, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher John Montague Meade, Michel Pairet
  • Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
    Publication number: 20030225118
    Abstract: The present invention relates to a new pharmaceutical combination for treating benign prostatic hyperplasia (BPH) or for the long-term prevention of acute urinary retention (AUR).
    Type: Application
    Filed: April 24, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Wolfgang Baiker, Ludwig Mehlburger
  • Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
    Publication number: 20030225079
    Abstract: The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.
    Type: Application
    Filed: May 8, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & CO. KG
    Inventors: Thomas Singer, Stefan Platz, Florian Colbatzky
  • Use of LTB4 antagonists in veterinary medicine
    Publication number: 20030225004
    Abstract: The invention relates to the use of LTB4 antagonists for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in companion and domesticated animals.
    Type: Application
    Filed: March 24, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Franz Birke, Kandace Matzek
  • Method of treating mucus hypersecretion
    Publication number: 20030220336
    Abstract: The invention relates to the use of p38 kinase inhibitors for the preparation of a pharmaceutical composition suitable for inhalation for the treatment of mucus hypersecretion. Furthermore the invention is directed to pharmaceutical compositions suitable for inhalation comprising p38 kinase inhibitors and to methods for the preparation thereof.
    Type: Application
    Filed: March 27, 2003
    Publication date: November 27, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Birgit Jung
  • Host cells having improved cell survival properties and methods to generate such cells
    Publication number: 20030219871
    Abstract: The present invention relates to genetically engineered mammalian host cells comprising an enhanced level of active anti-apoptosis genes and methods to generate such host cells. More particularly, the invention pertains to methods which modulate the level of anti-apoptosis active genes within host cells and to host cells showing an enhanced cell viability by delaying/inhibiting programmed cell death naturally occurring in such cells.
    Type: Application
    Filed: March 28, 2003
    Publication date: November 27, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Barbara Enenkel, Heiko Meents, Martin Fussenegger
  • FAP-activated anti-tumor compounds
    Publication number: 20030211979
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP&agr;, and the drug released by the enzymatic activity of FAP&agr; is cytotoxic or cytostatic under physiological conditions.
    Type: Application
    Filed: January 3, 2003
    Publication date: November 13, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Stefan Blech, Pilar Garin-Chesa, Martin Lenter, John Edward Park, Stefan Peters, Steffen Breitfelder